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Abstract
Background: European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE)
IV in primary care was a cross-sectional survey carried out by the European Society of Cardiology, EURObservational
Research Programme in 2014–2015 in 71 centres from 14 European countries. The main objective was to determine
whether the 2012 Joint European Societies’ guidelines on cardiovascular disease (CVD) prevention in people at high
CVD risk have been followed in clinical practice.
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Methods: Patients without a history of atherosclerotic disease started on either blood pressure and/or lipid and/or
glucose-lowering treatments were identified and interviewed at least six months after the start of medication.
Results: Medical notes of 6700 patients were reviewed, and 4579 patients (58.7% women; mean age 58.8 (standard
deviation (SD) 11.3) years) interviewed (interview rate 68.3%). Overall, 16.6% were smokers, 39.9% were overweight
(body mass index (BMI)25 and <30 kg/m2), 43.5% obese (BMI 30 kg/m2) and 63.9% centrally obese (waist circum-
ference of 88 cm for women, 102 cm for men). The medical risk factor control was very poor, with less than half
(42.8%) of the patients on blood pressure lowering medication reaching the target of <140/90mm Hg (<140/80mm Hg
in people with self-reported diabetes). Among treated dyslipidaemic patients only 32.7% attained the low-density lipo-
protein (LDL)-cholesterol target of <2.5mmol/l. Among people treated for type 2 diabetes mellitus, 58.5% achieved the
glycated haemoglobin (HbA1c) target of <7.0%.
Conclusion: The EUROASPIRE IV survey shows that large proportions of patients at high CVD risk have unhealthy
lifestyle habits and uncontrolled blood pressure, lipids and diabetes. The present data make it clear that more efforts
must be taken to improve cardiovascular prevention in people at high CVD risk.
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Introduction
The main objectives of cardiovascular disease (CVD)
prevention are to reduce morbidity and premature mor-
tality, improve quality of life and increase longevity.1
The European Society of Cardiology (ESC) together
with other partner societies has engaged in a compre-
hensive programme of CVD prevention in clinical prac-
tice for many years.2 Guidelines on this important topic
have been developed and updated at regular intervals
over the last 20 years: 1994, 1998, 2003, 2007 and
2012.1,3–6 It is emphasised that the highest clinical pri-
ority for prevention should be directed towards patients
with coronary or other atherosclerotic disease, and
those at high risk of developing CVD. Guideline imple-
mentation in daily practice has been evaluated with
four cross-sectional surveys called European Action
on Secondary and Primary Prevention by Intervention
to Reduce Events (EUROASPIRE) conducted under
the auspices of ESC Euro Heart Survey programme
in patients with coronary heart disease in 1995–1996,
1999–2000, 2006–2008 and in 2013–2015 through the
EURObservational Research Programme.7–15 For the
ﬁrst time, the two most recent surveys included individ-
uals free from any manifestations of CVD but living
with a high risk of developing CVD because of arterial
hypertension, dyslipidaemia or type 2 diabetes.12 The
aim of the primary care arm of EUROASPIRE IV was
to determine whether the 2012 Joint European Societies
(JES) guidelines on CVD prevention in people at high
cardiovascular risk are being followed in clinical
practice.
Study population and methods
Study design
The primary care arm of EUROASPIRE IV was
a cross-sectional survey carried out from January
2014–April 2015 in 71 primary care centres in Bosnia
and Herzegovina, Bulgaria, Croatia, Kazakhstan,
Lithuania, Poland, Portugal, Romania, Russian
Federation, Serbia, Spain, Sweden, Ukraine and the
UK. Within each country one or more geographical
areas with a deﬁned population were selected and a
sample of one or more general practices or health cen-
tres serving that population were identiﬁed according
to the structure of the local health services. Not all
countries that participated in the hospital arm of
EUROASPIRE IV were able to join the primary care
study due to logistics issues and diﬀerences in the
organisation of primary care.
Study population
Within each general practice men and women 18 to
<80 years at the time of identiﬁcation, without a
history of coronary or other atherosclerotic disease,
who had been prescribed one or more of the following
treatments: (a) blood pressure lowering drugs and/or
(b) lipid-lowering drugs and/or (c) glucose-lowering
(diet and/or oral drugs and/or insulin), 6 months to
<3 years prior to the date of interview, were identiﬁed
retrospectively from practice records. Patients sampled
by each of these treatments might have been using one
or more of the other drug therapies.
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Data collection
Centrally trained research staﬀ undertook data collec-
tion using standardised methods and the same instru-
ments in all centres. They reviewed patient medical
notes and interviewed and examined the patients at
the general practice or home at least six months after
the prescription of blood pressure, lipid or glucose-
lowering therapy.
Height and weight (scales 701 and measuring stick
model 220; SECA Medical Measuring Systems and
Scales, Birmingham, UK) and waist circumference16
(metal tape applied horizontally at the point midway
in the mid-axillary line between the lowest rim of the rib
cage and the superior iliac crest) were recorded. Being
overweight was deﬁned as a body mass
index (BMI)25 to <30 kg/m2 and obesity as
BMI30 kg/m2. Abdominal overweight was deﬁned as
a waist circumference 94 cm in men, 80 cm in
women and central obesity as a waist circumference
of 88 cm for women and 102 cm for men.
Blood pressure was measured twice on the right upper
arm in a sitting position using an automatic digital sphyg-
momanometer (Omron M6; OMRON Corporation,
Kyoto, Japan) and the mean was used for the analyses.
Raised blood pressure was deﬁned as systolic blood pres-
sure (SBP)140mm Hg and/or diastolic blood pressure
(DBP)90mm Hg (140/80mm Hg in patients with
diabetes).
Breath carbon monoxide (CO) was measured in ppm
using a smokerlyser (Model Microþ Bedfont Scientiﬁc,
Harrietsham, UK). Smoking was deﬁned as self-
reported smoking, and/or a breath CO exceeding
10 ppm.17
Habitual physical activity was assessed with the fol-
lowing question:
Which of the following four alternatives describes your
level of activity outside work in the best way?
a. No physical activity weekly,
b. Only light physical activity in most weeks,
c. Vigorous physical activity at least 20minutes
once or twice a week,
d. Vigorous physical activity for at least 20min-
utes three or more times a week.
Fasting (10 h) venous blood samples were taken in
the sitting position with light stasis into a tube contain-
ing clot activator (Venosafe, Terumo Europe, Leuven,
Belgium) for lipid assays and into a potassium
Ethylenediaminetetraacetic acid (EDTA) tube
(Venosafe) for glycated haemoglobin (HbA1c) assay.
Serum was separated by centrifuging at 2000 g for
10min at room temperature and aliquoted into two
bar-code-labelled tubes that were stored locally together
with whole EDTA blood tubes at a minimum of –70C
for subsequent transportation to the central laboratory
at the Disease Risk Unit, National Institute for Health
and Welfare, Helsinki, Finland where all measurements
were performed on a clinical chemistry analyser
(Architect c8000; Abbott Laboratories, Abbott Park,
Illinois, USA). The laboratory has been accredited by
the Finnish Accreditation Service and fulﬁls the require-
ments of the standard SFS-EN ISO/IEC 17025:2005.
Total and high density lipoprotein cholesterol
(HDL-C) and triglycerides were analysed in serum,
and HbA1c in whole blood with the following methods:
enzymatic method for total cholesterol, a homogenous
method for direct measurement of HDL-C, an enzym-
atic glycerol phosphate oxidase method for triglycer-
ides, and an immunoturbidimetric method for
HbA1c. LDL cholesterol (LDL-C) was calculated
according to Friedewald’s formula.18 Elevated LDL-C
concentration was deﬁned as 2.5mmol/l. Elevated
HbA1c was deﬁned as 7.0% (Diabetes Control and
Complications Trial (DCCT)).
The laboratory takes part in the Lipid
Standardization Program organized by Centers for
Disease Control and Prevention (CDC), Atlanta,
Georgia, USA and External Quality Assessment
Schemes organized by Labquality, Helsinki, Finland.
During the course of the study, comprising two
months in 2013, the coeﬃcient of variation
(meanstandard deviation (SD)) and systematic error
(bias) (meanSD) were 1.3% 0.2 and 1.7% 1.1 for
total cholesterol, 1.6% 0.5 and –1.5% 1.6 for HDL-
C, 2.3% 0.1 and –1.2% 2.6 for triglycerides, and
1.9% 0.1 and 1.4% 0.2 for HbA1c, respectively.
Data management
The EURObservational Research Programme at the
European Heart House (Nice, France) was in charge
of data management. All data were collected electron-
ically through web-based data entry using a unique
identiﬁcation number for country, centre and individ-
ual. The data were submitted via the Internet to the
data management centre where checks for complete-
ness, internal consistency and accuracy were run. All
data were stored under the provisions of the National
Data Protection Regulations.
Statistical analyses
Sample size calculations indicated that a sample of 400
patients attending interview was suﬃcient to estimate
prevalence of risk factors with precision of at least 5%
and with a conﬁdence interval of 95%. Descriptive
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statistics were used to estimate the prevalence of risk
factors and medication use by country, gender and age
at interview. All statistical analyses were undertaken
using SAS statistical software (release 9.4) in the
Department of Public Health, Ghent University,
Belgium.
Ethical procedures
The local ethics committees of all participating coun-
tries approved the EUROASPIRE IV protocol.
Written, informed consent was obtained from each
participant.
Outcome measures
The main outcome measures were the proportions of
high CVD risk individuals achieving the lifestyle and
risk factor targets deﬁned in the 2012 JES guidelines on
CVD prevention in clinical practice: not smoking,
healthy food choices and be physically active; a
BMI<25 kg/m2; blood pressure<140/90mm Hg
(<140/80mm Hg in patients with diabetes), LDL-
C<2.5mmol/l, and appropriate use of cardioprotective




A total of 6700 medical notes were reviewed and 4579
patients interviewed after the start of drug treatment
(interview rate 68.3%). The comparison of patients
interviewed with those who were not, showed that
women and patients older than 60 years were signiﬁ-
cantly more likely to attend the interview. Of those
interviewed, the mean (SD) age was 58.8 (11.3) years
and 2647 (57.8%) were women (Table 1).
Study outcomes
Lifestyle. The prevalence of smoking, obesity and central
obesity is presented in Table 2. The overall prevalence
of smoking (self-reported and/or CO in breath
>10 ppm) was 16.6% (men 22.0%, women 12.7%)
and higher in patients <60 years of age. Less than
half of current smokers (42.2%) reported having the
intention to quit smoking within the next six months.
Although the majority of smokers had been oﬀered
personal advice by a health professional to stop smok-
ing (73.5%), only 11.1% had been referred to smoking
cessation clinic. Advice to use nicotine replacement
therapy (NRT) had been given to 11.6% of the smokers
Table 1. Distribution of study population by country, age and gender.
Female, % (n) Age, mean (SD) Age60 years, % (n)
Centre
Bosnia and Herzegovinad 53.2 (118/222) 62.3 (8.9) 58.1 (129/222)
Bulgaria 49.5 (93/188) 60.0 (12.2) 60.6 (114/188)
Croatia 57.9 (232/401) 62.7 (10.1) 64.1 (257/401)
Kazakhstan 68.3 (285/417) 57.2 (9.1) 39.8 (166/417)
Lithuania 55.8 (223/400) 54.0 (9.1) 28.3 (113/400)
Poland 55.8 (261/468) 56.8 (10.5) 42.9 (201/468)
Portugal 53.8 (211/392) 65.9 (9.4) 75.5 (296/392)
Romania 60.2 (239/397) 55.5 (12.5) 39.5 (157/397)
Russian Federation 71.6 (290/405) 56.0 (10.1) 30.4 (123/405)
Serbia 57.2 (103/180) 51.0 (14.2) 30.6 (55/180)
Spain 46.6 (75/161) 66.9 (8.9) 76.4 (123/161)
Sweden 51.3 (77/150) 64.9 (9.0) 72.7 (109/150)
Ukraine 64.1 (263/410) 56.8 (11.4) 43.4 (178/410)
United Kingdom 45.6 (177/388) 61.0 (11.5) 55.9 (217/388)
Reasons for inclusion
Blood pressure lowering therapy 59.2 (1920/3243) 58.9 (11.0) 48.5 (1574/3243)
Lipid-lowering therapy 57.0 (676/1186) 60.8 (10.7) 56.2 (667/1186)
Glucose-lowering therapy 52.1 (570/1094) 59.7 (11.7) 52.7 (577/1094)
All 57.8 (2647/4579) 58.8 (11.3) 48.9 (2238/4579)
SD: standard deviation.
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and bupropion and varenicline had been prescribed to
2.6% and 2.9% of them, respectively.
Overall, 39.9%of patients (men 45.6%,women 35.9%)
were overweight and 43.5% (men 40.4%, women 45.7%)
were obese. The prevalence of abdominal overweight was
84.9%, higher inwomen (89.8%) than inmen (78.1%) and
63.9% (men 52.3%, women 72.3%) were centrally obese.
One in ﬁve of obese patients (20.1%) have never been told
by a health professional that theywere overweight and just
over half (52.2%) planned to lose weight in the next
month. About two-thirds (65.2%) of obese patients had
received a personal dietary recommendation by a health
professional and 59.0% were advised to participate in
regular physical activity but less than half of them took
steps to loseweight by increasingphysical activity (39.3%).
In this survey, less than a ﬁfth (18.4%) of patients (men
23.6%,women 13.0%) performed vigorous physical activ-
ity during at least 20min on three or more times/week. In
addition, less than one in ﬁve patients (14.1%) had been
advised to attend some form of CVD prevention pro-
gramme. The reported lifestyle changes are presented in
Table 3.
Blood pressure. Just over half of patients not using blood
pressure lowering medication had a normal blood pres-
sure (total 53.8%, men 44.0%, women 62.0%). Overall,
82.7% of patients were on blood pressure lowering medi-
cation at the time of interview. However, less than half
(42.8%,men 35.0%, women 48.4%) reached the target of
<140/90mm Hg (<140/80mm Hg in people with dia-
betes) (Table 4). Four of ﬁve patients (85.4%) on blood
pressure lowering medication were aware of their blood
pressure level and 67.9%of the recommended blood pres-
sure target. The most commonly prescribed medication
were inhibitors of renin angiotensin systems (angiotensin-
converting-enzyme (ACE) inhibitors/ angiotensin recep-
tor blockers (ARBs); 79.8%), followed by beta-blockers
(36.8%), diuretics (38.3%) and calcium channel blockers
(29.1%).
Lipids. One third of the patients (35.6%) were on lipid-
lowering drug therapy. Of these patients 96.1% were on
statins, 4.6% on ﬁbrates, 1.4% on ezetimibe and 0.4%
on other lipid-lowering drugs. Only a minority of those
prescribed lipid-lowering drugs reached the LDL-C
target of <2.5mmol/l (total 32.7%, men 39.9%,
women 27.0%) (Table 5). Less than half (47.1%) of
patients on lipid-lowering medication had been
informed of their cholesterol levels and 38.7% were
aware of their target. Only one in 10 (10.7%) of the
patients without any lipid-lowering medication had a
LDL-C<2.5mmol/l (men 12.3%, women 9.6%).
Table 2. Prevalence of smoking, obesity and central obesity by country, age and gender.
Smokinga% (n) Obesityb % (n) Central obesityc % (n)




20.2 (21/104) 5.9 (7/118) 14.5 (12/83) 20.2 (20/99) 18.3 (11/60) 73.5 (61/83)
Bulgaria 29.5 (28/95) 15.1 (14/93) 60.0 (57/95) 39.8 (37/93) 82.1 (78/95) 89.2 (83/93)
Croatia 20.7 (35/169) 21.1 (49/232) 45.0 (76/169) 44.4 (103/232) 57.4 (97/169) 69.8 (162/232)
Kazakhstan 33.3 (44/132) 14.0 (40/285) 45.5 (60/132) 44.2 (126/285) 56.8 (75/132) 79.9 (227/284)
Lithuania 26.0 (46/177) 10.8 (24/223) 54.2 (96/177) 55.5 (122/220) 65.5 (116/177) 74.1 (163/220)
Poland 26.1 (54/207) 19.2 (50/261) 42.7 (88/206) 37.5 (98/261) 46.4 (96/207) 68.2 (178/261)
Portugal 12.7 (23/181) 7.6 (16/211) 33.5 (60/179) 42.2 (89/211) 57.9 (103/178) 76.3 (161/211)
Romania 13.9 (22/158) 5.9 (14/239) 40.5 (64/158) 51.9 (124/239) 39.9 (63/158) 71.1 (170/239)
Russian Federation 31.3 (36/115) 12.4 (36/290) 48.7 (56/115) 59.6 (171/287) 44.1 (49/111) 70.6 (199/282)
Serbia 46.8 (36/77) 34.0 (35/103) 24.3 (17/70) 22.5 (23/102) 48.5 (16/33) 62.7 (37/59)
Spain 12.8 (11/86) 16.0 (12/75) 40.7 (35/86) 64.0 (48/75) 70.9 (61/86) 80.0 (60/75)
Sweden 12.3 (9/73) 6.5 (5/77) 35.6 (26/73) 29.9 (23/77) 57.5 (42/73) 63.6 (49/77)
Ukraine 25.9 (38/147) 4.2 (11/263) 36.1 (53/147) 54.0 (142/263) 41.5 (61/147) 68.4 (180/263)
United Kingdom 10.9 (23/211) 13.0 (23/177) 32.2 (68/211) 40.7 (72/177) 44.1 (93/211) 65.9 (116/176)
Age
<60 years 29.5 (305/1035) 17.5 (228/1306) 42.9 (440/1026) 44.7 (581/1299) 51.0 (503/986) 70.4 (884/1255)
60 years 13.5 (121/897) 8.1 (108/1341) 37.5 (328/875) 46.7 (617/1322) 53.8 (458/851) 74.0 (962/1300)
All 22.0 (426/1932) 12.7 (336/2647) 40.4 (768/1901) 45.7 (1198/2621) 52.3 (961/1837) 72.3 (1846/2555)
aSelf-reported smoking or carbon monoxide (CO) in breath >10 ppm; bbody mass index 30 kg/m2; cwaist circumference 88/102 cm for women/
men; dthe percentage of missing values in waist circumference in Bosnia and Herzegovina makes gender comparisons difficult.
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Diabetes. The proportion of study patients with self-
reported diabetes at interview was 27.7%, higher in
men (31.9%) than in women (24.7%). The majority
(75.1%) were on oral glucose-lowering drugs while
18.3% had been prescribed insulin and 8.6% diet
only. Somewhat more than half (58.5%) had a
HbA1c<7.0% (Table 6), and a minority (24.3%) had
been informed of their HbA1c target. In people with
diabetes, statins were prescribed in 40.8% and inhibi-
tors of the renin angiotensin system in 63.4%.
Discussion
Principal findings
There is a wealth of scientiﬁc evidence that lifestyle
adaptations and CVD risk factor management can
reduce the risk of future atherosclerotic events in
people at high CVD risk.1,19–24 Still, as shown by
EUROASPIRE IV, the implementation of evidence-
based CVD prevention guidelines in general practice
is far from optimal. A large majority of high CVD
risk patients in Europe are failing to achieve their life-
style, blood pressure, lipids and diabetes goals. This is
true even considering the large variation between coun-
tries in lifestyle and risk factor management and in the
use of cardioprotective therapies. The high prevalences
of smoking, obesity and central obesity are major
causes for concern. Only a small minority of high-risk
patients were advised to participate in a CVD preven-
tion programme and the majority of those on blood
pressure and lipid-lowering medication did not achieve
the targets deﬁned in the Fifth Joint European
Societies’ guidelines on CVD prevention. Moreover
many of the patients were not informed on their treat-
ment targets. Thus there is a substantial gap between
Table 3. Reported lifestyle changes taken by patients to reduce their risk of heart disease within the last three years by gender.
Lifestyle changes % (n)
Men Women All
Smokinga
Abstinence 19.2 (77/401) 21.8 (68/312) 20.3 (145/713)
Reduction 46.6 (190/408) 49.8 (158/317) 48.0 (348/725)
Smoking cessation clinic 2.7 (11/407) 3.8 (12/315) 3.2 (23/722)
NRT 6.1 (25/408) 6.6 (21/316) 6.4 (46/724)
Bupropion 1.0 (4/405) 1.0 (3/314) 1.0 (7/719)
Varenicline 1.0 (4/405) 1.6 (5/314) 1.3 (9/719)
In patients with BMI 30 kg/m2
Reduction of fat 74.9 (747/997) 74.5 (689/925) 74.7 (1436/1922)
Reduction of calories 63.8 (627/982) 61.1 (557/911) 62.5 (1184/1893)
Increased everyday physical activity 40.2 (400/995) 38.4 (358/932) 39.3 (758/1927)
In patients using BP lowering medication
Special diet 46.0 (699/1520) 47.3 (1025/2165) 46.8 (1724/3685)
Reduction of salt 70.6 (1080/1530) 75.2 (1640/2180) 73.3 (2720/3710)
Increased everyday physical activity 41.4 (635/1535) 41.0 (892/2178) 41.1 (1527/3713)
In patients using lipid-lowering medications
Special dietb 54.6 (388/710) 64.9 (569/877) 60.3 (957/1587)
Reduction of fat 72.8 (525/721) 78.9 (697/883) 76.2 (1222/1604)
More fruit and vegetables 79.6 (575/722) 80.9 (711/879) 80.3 (1286/1601)
More fish 64.4 (462/717) 64.8 (568/876) 64.7 (1030/1593)
Increased everyday physical activity 44.7 (322/720) 42.7 (376/880) 43.6 (698/1600)
In patients with diabetes
Reduction of fat 73.9 (442/598) 80.0 (509/636) 77.1 (951/1234)
More fruit and vegetables 79.1 (446/589) 83.0 (526/634) 81.1 (992/1223)
Less sugar 83.7 (503/601) 83.8 (538/642) 83.7 (1041/1243)
Less alcohol 62.4 (369/591) 52.6 (332/631) 57.4 (701/1222)
Increased everyday physical activity 45.7(274/600) 47.9(307/641) 46.8 (581/1241)
BMI: body mass index; BP: blood pressure; NRT: nicotine replacement therapy.
aChange during the last three years reported by smokers; bprescribed by a doctor or other health professional.
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evidence-based guidelines and everyday clinical
practice.
In the primary care arm of EUROASPIRE IV,
nearly one-ﬁfth of high-risk patients were smokers at
the time of interview. Of worry is that the prevalence of
smoking was higher in younger patients and that a
large majority of those smoking at the time of identiﬁ-
cation as at high CVD risk still smoked at the interview.
Stopping smoking is the most cost-eﬀective strategy for
CVD prevention.1,19 Yet, only a minority of smokers
attended smoking cessation clinic and/or were pre-
scribed pharmacotherapy. Despite being labelled as
high CVD risk, only two-ﬁfths of smokers intended to
quit smoking within the next six months following
interview.
Healthy diet and weight reduction in overweight and
obese people is recommended in order to reduce blood
pressure, lipids and risk of type 2 diabetes mellitus.1,20
A large majority of the patients in EUROASPIRE IV
were overweight or obese and two-thirds centrally
obese. Although a majority had attempted dietary
amendments to lose weight less than half reported on
increasing everyday physical activity. Indeed less than
20% of the patients reported performing vigorous
physical activity for at least 20minutes three or more
times a week.
Good blood pressure, lipid and glycaemic control
reduce the risk of CVD. 1,21–25 In this survey, the man-
agement of blood pressure was poor with less than half
of patients on blood pressure lowering medication
achieving recommended targets. Importantly, a large
proportion of patients selected as at high risk because
of treated hyperlipidaemia and/or diabetes had elevated
blood pressure without any prescription of blood pres-
sure reducing therapy. The control of LDL-C in
patients on lipid-lowering medication was inadequate,
with only 30% of patients achieving the target.
Considerable gender diﬀerences were observed in lipid
and blood pressure goal achievement, with a better con-
trol of lipids in men and blood pressure in women.
Similarly to blood pressure, many patients identiﬁed
as at high risk because of treated hypertension and/or
diabetes had elevated LDL-C without any lipid-lower-
ing medication. Accordingly many of the
EUROASPIRE IV patients with high blood pressure
and/or high cholesterol seemed to be unaware of or
indeed not diagnosed as having hypertension and/or
dyslipidaemia. An explanation may be that general
Table 4. Control of blood pressure by country, age and gender.
Blood pressure at goala (%) n
No BP lowering medicationb On BP lowering medicationb
Men Women Men Women
Centre
Bosnia and Herzegovina 0.0 (0/3) 100 (4/4) 39.6 (40/101) 41.2 (47/114)
Bulgaria 32.6 (31/95) 37.6 (35/93)
Croatia 37.5 (6/16) 66.7 (18/27) 26.8 (41/153) 40.2 (82/204)
Kazakhstan 46.7 (7/15) 72.0 (18/25) 39.3 (46/117) 55.4 (144/260)
Lithuania 29.0 (9/31) 58.8 (20/34) 32.9 (47/143) 45.7 (85/186)
Poland 31.1 (23/74) 60.9 (53/87) 29.2 (38/130) 41.0 (71/173)
Portugal 52.4 (11/21) 52.9 (9/17) 27.7 (44/159) 44.8 (87/194)
Romania 50.0 (26/52) 57.4 (39/68) 22.6 (24/106) 32.2 (55/171)
Russian Federation 69.2 (9/13) 76.5 (13/17) 58.6 (58/99) 71.8 (188/262)
Serbia 56.7 (17/30) 67.6 (25/37) 62.2 (28/45) 69.2 (45/65)
Spain 50.0 (4/8) 59.1 (13/22) 37.2 (29/78) 32.1 (17/53)
Sweden 0.0 (0/2) 40.0 (4/10) 30.9 (21/68) 57.6 (38/66)
Ukraine 33.3 (5/15) 50.0 (9/18) 38.2 (50/131) 47.3 (116/245)
United Kingdom 51.9 (42/81) 65.5 (38/58) 36.0 (45/125) 47.9 (57/119)
Age
<60 years 46.0 (120/261) 65.2 (165/253) 39.9 (305/764) 54.7 (568/1039)
60 years 39.0 (39/100) 57.3 (98/171) 30.2 (237/786) 42.8 (499/1166)
All 44.0 (159/361) 62.0 (263/424) 35.0 (542/1550) 48.4 (1067/2205)
BP: blood pressure; DBP: diastolic BP; SBP: systolic BP.
aSBP/DBP<140/90mm Hg (<140/80mm Hg in patients with diabetes); bBP lowering medication: angiotensin-converting-enzyme (ACE) inhibitors,
angiotensin receptor blockers, beta-blockers, calcium channel blockers, diuretics, alpha-blockers.
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practitioners still have an unifactorial approach to
CVD risk based on the old fashioned medical paradigm
seeing single risk factors as a disease instead of calcu-
lating the total CVD risk as recommended in the pre-
vention guidelines. It underlines that further eﬀorts are
needed to underline the importance of screening for
other CVD risk factors and estimate the global CVD
risk in each patient with an already diagnosed CVD
risk factor. A multifactorial risk approach is important
because the CVD risk results from interaction of many
risk factors, with modest increases in multiple risk fac-
tors more harmful than a signiﬁcantly raised level of a
single risk factor and that the concept of continuous
risk should replace the dichotomous classiﬁcation of
risk factors. Looking at the number of risk factors
(smoking, elevated blood pressure or cholesterol and
diabetes) only 8.2% of patients in EUROASPIRE IV
had only one risk factor, while 58.0% had two, 30.6%
three and 3.2% four risk factors. Thus a substantial
proportion of patients on blood pressure and/or lipid-
lowering medication should have been considered as at
high CVD risk. It underlines the importance to always
look at the total CVD risk while treating individual risk
factors since the beneﬁts of preventive measures are
greatest in people at the highest absolute CVD risk.
Such approach will also avoid treatment of single risk
factors in people at low multifactorial risk.
There are several explanations for the poor blood
pressure and lipid control, including low-dose prescrip-
tions, inadequate up-titration, poor patients adherence
or therapeutic inertia deﬁned as the failure of phys-
icians to initiate or intensify therapy when therapeutic
targets are not reached. In addition, monotherapy is
usually insuﬃcient for treating hypertension and
many patients would require combination of two or
more blood pressure lowering medications. The major-
ity of patients in the survey (85%) reported that they
took their medication ‘nearly all of the time (90%)’ or
‘all of the time (100%)’. In such setting further possi-
bilities to reduce recurrent cardiovascular events would
be to optimise the dose of evidence-based medication
and to, use combination therapies combining e.g. sev-
eral blood pressure lowering compounds in one tablet.
According to the guidelines, people with type 2 dia-
betes should be managed as at high CVD risk. The
importance of glucose control in patients with diabetes
has been debated as regards protection from macro-
vascular but is still valid for the avoidance of micro-
vascular complications. There are, however, reasons to
believe that glucose control is of particular value in
Table 5. Control of low-density lipoprotein (LDL) cholesterol by country, age and gender.
LDL cholesterol at goala (%) n
No lipid-lowering medicationb On lipid-lowering medicationb
Men Women Men Women
Centre
Bosnia and Herzegovina 16.3 (8/49) 10.9 (7/64) 29.0 (9/31) 22.2 (8/36)
Bulgaria 12.2 (6/49) 11.1 (6/54) 42.1 (8/19) 13.6 (3/22)
Croatia 10.3 (9/87) 4.8 (7/145) 41.8 (23/55) 34.8 (24/69)
Kazakhstan 11.0 (13/118) 7.1 (19/268) 50.0 (2/4) 25.0 (2/8)
Lithuania 5.9 (6/102) 4.2 (6/143) 13.5 (5/37) 17.4 (12/69)
Poland 5.6 (7/126) 6.8 (10/148) 33.8 (23/68) 26.2 (28/107)
Portugal 8.5 (6/71) 8.0 (7/87) 32.7 (33/101) 17.3 (19/110)
Romania 15.7 (14/89) 19.5 (26/133) 37.9 (22/58) 33.3 (33/99)
Russian Federation 9.1 (7/77) 8.7 (18/206) 53.3 (8/15) 17.4 (8/46)
Serbia 25.0 (10/40) 17.5 (11/63) 33.3 (5/15) 25.0 (5/20)
Spain 26.3 (5/19) 23.5 (4/17) 49.1 (27/55) 28.6 (14/49)
Sweden 4.8 (2/42) 2.0 (1/49) 44.4 (12/27) 33.3 (9/27)
Ukraine 18.5 (17/92) 13.6 (24/176) 46.2 (18/39) 27.8 (20/72)
United Kingdom 22.7 (17/75) 13.8 (12/87) 51.6 (63/122) 43.2 (35/81)
Age
<60 years 11.2 (70/627) 10.8 (98/909) 34.0 (87/256) 26.1 (78/299)
60 years 13.9 (57/409) 8.2 (60/731) 43.8 (171/390) 27.5 (142/516)
All 12.3 (127/1036) 9.6 (158/1640) 39.9 (258/646) 27.0 (220/815)
aLDL cholesterol<2.5mmol/l; blipid-lowering medication: statins, fibrates, bile acid sequestrants (anion exchange resins), nicotinic acid and its derivates,
cholesterol absorption inhibitors.
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patients with short diabetes duration and still without
any CVD manifestations.25 It is therefore unsatisfac-
tory that less than 60% of patients with self-reported
diabetes achieved the target of HbA1c (<7.0%). The
cardioprotective medications recommended in patients
with diabetes mellitus include ACE inhibitors/ARBs to
reduce blood pressure to target and statins to reduce
CVD risk. In this survey less than 30% of patients with
known diabetes were on ACE inhibitors/ARBs and
only 40% on statins.
Comparison with other surveys
The slow implementation of primary prevention
guidelines in clinical practice has been reported in simi-
lar surveys in Europe and the USA.26–35 However,
some studies were focused on the control of a single
risk factor (blood pressure or lipids) and there is limited
comparable information on management and control
of CVD risk factors in patients at high CVD risk
across Europe. Blood pressure control in
EUROASPIRE IV was slightly better than in the
EURIKA study conducted in 2009 selecting 7641
patients from 12 European countries free of clinical
CVD and with at least one major CVD risk factor.26
Among patients with treated hypertension 38.8%
achieved a blood pressure of <140/90mm Hg (<130/
90mm Hg in people with diabetes), which may be com-
pared to 42.8% in EUROASPIRE IV. Among treated
patients with dyslipidaemia, 41.2% of patients in
EURIKA attained LDL-C of <3mmol/l, compared
to 32.7% achieving LDL-C of <2.5mmol/l in
EUROASPIRE IV. An international cross-sectional
observational study conducted in 3723 individuals at
high risk of CVD in nine European countries found
that 50.6% had elevated blood pressure >140/90mm
Hg, 59.8% had total cholesterol >5mmol/l, 30.5%
were smokers, 31.4% were obese, 76.5% were over-
weight, and 14.6% had a fasting glucose levels
>6.1mmol/l.27
Strengths and limitations
The ﬁndings of the EUROASPIRE IV survey should be
considered within the context of some limitations. The
most important is that patients were identiﬁed from
selected geographical areas and a convenience sample
of general practices according to the structure of local
health services. Therefore, the patients are not neces-
sarily representative of all high-risk patients cared for
in the primary care setting of each country. Another
limitation is the diagnostic characteristics. All patients
were already on blood pressure and/or lipid-lowering
medication and/or had diabetes mellitus averting the




Bosnia and Herzegovina 38.9 (14/36) 35.5 (11/31) 37.3 (25/67)
Bulgaria 56.2 (9/16) 73.3 (11/15) 64.5 (20/31)
Croatia 48.3 (28/58) 48.6 (34/70) 48.4 (62/128)
Kazakhstan 28.6 (8/28) 55.6 (20/36) 43.8 (28/64)
Lithuania 77.3 (58/75) 79.3 (65/82) 78.3 (123/157)
Poland 80.0 (28/35) 75.8 (25/33) 77.9 (53/68)
Portugal 63.1 (53/84) 60.6 (40/66) 62.0 (93/150)
Romania 62.5 (10/16) 68.8 (33/48) 67.2 (43/64)
Russian Federation 60.0 (18/30) 67.5 (27/40) 64.3 (45/70)
Serbia 56.0 (14/25) 43.6 (17/39) 48.4 (31/64)
Spain 71.8 (28/39) 70.6 (24/34) 71.2 (52/73)
Sweden 50.0 (12/24) 70.6 (12/17) 58.5 (24/41)
Ukraine 33.3 (11/33) 28.8 (17/59) 30.4 (28/92)
United Kingdom 62.7 (42/67) 48.8 (20/41) 57.4 (62/108)
Age
<60 years 57.4 (148/258) 57.8 (144/249) 57.6 (292/507)
60 years 60.1 (185/308) 58.6 (212/362) 59.3 (397/670)
All 58.8 (333/566) 58.3 (356/611) 58.5 (689/1177)
HbA1c: glycated haemoglobin.
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assessment of the total multifactorial risk by means of
SCORE or similar risk calculators. However, a large
majority of patients identiﬁed on the basis of being
on blood pressure and/or lipid-lowering medication
and/or having diabetes did indeed have more than
one uncontrolled risk factor, which will put them at
high risk of developing CVD. The proﬁle of patients
in primary care may diﬀer between centres, which for
instance can explain diﬀerences in age distributions
between countries. Since a comparison between coun-
tries was not the aim of the EUROASPIRE surveys no
formal statistical testing adjusting for age was per-
formed. We believe that our sample reﬂects a typical
European patient population in the age range 18–80
years. The tables show country-speciﬁc results just to
inform participating countries of their own results.
The main strength of the EUROASPIRE IV survey
is that the data are not just based on a review of med-
ical notes from general practices but on face-to-face
interviews and standardised examinations, including
central laboratory analyses. Patients were interviewed
at least six months after starting blood pressure, lipid-
lowering or diabetes medication which is suﬃcient time
to achieve guidelines deﬁned targets. Therefore this
survey provides relevant information on preventive
care in everyday general practice.
Conclusions
The implementation of evidence-based guidelines on
primary prevention in everyday clinical practice is
poor. Large proportions of patients at high CVD risk
have high prevalences of overweight, obesity and cen-
tral obesity and, in addition, blood pressure, lipids and
diabetes levels above the targets deﬁned in the preven-
tion guidelines. There is a large heterogeneity between
countries in lifestyle and risk factor management that
may be explained by the diﬀerences in the characteris-
tics of study populations, drug prescription policies and
healthcare systems between countries. It is surprising
that people living with high risk for CVD, but still no
manifestations of CVD, get such unsatisfactory protec-
tion from future illness. The present data strongly
underline the need for intense eﬀorts to be taken not
only to issue and update guidelines on cardiovascular
prevention but also to enhance their implementation.
Considering the present results the latter seems to be an
issue that should be heavily prioritised. Such eﬀorts
should include information on the distribution of
knowledge on the guidelines among diﬀerent parts of
the health care providers providing comprehensive risk
factors management, in order to reduce the risk of
CVD. There is an urgent need for CVD prevention
centres to have multidisciplinary teams of health care
professionals, focusing on all aspects of lifestyle and
risk factor management in order to reduce the risk of
CVD and improve the standards in CVD prevention in
Europe.
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